4//SEC Filing
Brazzell Romulus K 4
Accession 0001415889-23-009135
CIK 0001479419other
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 8:00 PM ET
Size
28.8 KB
Accession
0001415889-23-009135
Insider Transaction Report
Form 4
Brazzell Romulus K
SEE REMARKS
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2023-05-31−2,999→ 0 totalExercise: $259.50Exp: 2029-01-01→ Common Stock (2,999 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−942→ 0 totalExercise: $750.00Exp: 2027-07-18→ Common Stock (942 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−2,047→ 0 totalExercise: $167.00Exp: 2026-06-17→ Common Stock (2,047 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−2,199→ 0 totalExercise: $343.00Exp: 2031-01-03→ Common Stock (2,199 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−308→ 0 totalExercise: $260.50Exp: 2025-10-02→ Common Stock (308 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−1,399→ 0 totalExercise: $643.00Exp: 2028-02-06→ Common Stock (1,399 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−2,399→ 0 totalExercise: $192.00Exp: 2030-01-01→ Common Stock (2,399 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−864→ 0 totalExercise: $68.50Exp: 2032-01-03→ Common Stock (864 underlying) - Award
Common Stock
2023-05-31+17,916→ 36,452 total - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−4,759→ 0 totalExercise: $68.50Exp: 2032-01-03→ Common Stock (4,759 underlying)
Footnotes (12)
- [F1]On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 13,130 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 4,786 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.
- [F10]The canceled option was granted on January 4, 2021 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
- [F11]The canceled option was granted on January 3, 2022 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
- [F12]The canceled option was granted on January 3, 2022 and provided for the purchase of up to 2,160 shares of common stock of the issuer based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters, of which, prior to the option exchange program, options to purchase 576 shares had vested, options to purchase 1,152 shares had been forfeited and options to purchase up to 432 shares were unvested assuming maximum level of achievement (options to purchase 288 shares were unvested assuming target level of achievement). The vested portion of the option and the unvested portion of the option assuming target level of achievement were eligible for the issuer's option exchange program.
- [F2]Includes 30,900 unvested RSUs.
- [F3]The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.
- [F4]The cancelled option was granted on October 2, 2015 and provided for vesting over four years, with 25% of the shares underlying the option vested on October 2, 2016 and an additional 1/48th vested at the end of each successive one-month period thereafter.
- [F5]The cancelled option was granted on June 17, 2016 and provided for vesting over four years, with 25% of the shares underlying the option vested on June 17, 2017 and an additional 1/48th vested at the end of each successive one-month period thereafter.
- [F6]The canceled option was granted on July 19, 2017 and provided for vesting over four years with 1/48th of the shares underlying the option vested on August 31, 2017 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter.
- [F7]The canceled option was granted on February 7, 2018 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
- [F8]The canceled option was granted on January 2, 2019 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
- [F9]The canceled option was granted on January 2, 2020 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
Documents
Issuer
Kala Pharmaceuticals, Inc.
CIK 0001479419
Entity typeother
Related Parties
1- filerCIK 0001298079
Filing Metadata
- Form type
- 4
- Filed
- Jun 1, 8:00 PM ET
- Accepted
- Jun 2, 8:00 PM ET
- Size
- 28.8 KB